Fiche publication
Date publication
juillet 1997
Journal
Leukemia
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MERLIN Jean-Louis
Tous les auteurs :
Chevillard S, Vielh P, Validire P, Marie JP, Faussat AM, Barbu V, Bayle C, Bénard J, Bonnal C, Boutonnat J, Calvo F, Charrier J, Clary A, Colosetti P, Danel-Moore L, Decrémoux P, Delvincourt C, Finat-Duclos F, Genne P, Kataki A, Kouyoumdjian JC, Lacave R, Maugard C, Merlin JL, Robert J
Lien Pubmed
Résumé
Since there is no consensus on the techniques for multidrug resistance (MDR) phenotype evaluation, many discrepancies concerning the importance and frequency of mdr1 gene expression in leukemias and solid tumors are observed in the literature. In order to establish an inter-laboratory consensus in France, a multicenter study was carried out to propose further guidelines for MDR phenotype evaluation. The techniques used by the 38 laboratories participating in the trial were: immunodetection (immunohisto and/or cytochemistry, flow cytometry), functional tests, reverse transcription-polymerase chain reaction (RT-PCR) or Northern blot. We present the results obtained by 19 laboratories concerning the measurement of mdr1 gene expression assessed by RT-PCR or Northern blot in: (1)19 samples of tumor cells obtained from leukemic patients; (2) six solid tumor samples obtained at surgery; (3) eight cell lines exhibiting variable levels of resistance, and; (4)10 preparations of RNA and of cDNA obtained from solid tumors. Standardization of the RT-PCR technique and preliminary results comparing RT-PCR with immunohistochemistry in solid tumors are also reported.
Mots clés
DNA, Complementary, analysis, Humans, Immunohistochemistry, Leukemia, drug therapy, Neoplasms, drug therapy, P-Glycoprotein, genetics, Polymerase Chain Reaction, standards, RNA, analysis
Référence
Leukemia. 1997 Jul;11(7):1095-106
